Clinilabs, LLC, a leading full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and medical technology development, today announced the appointments of David Hagerman as Chief Financial Officer (CFO) and Jeanine Falinski as Senior Vice President of Commercial Development.
These strategic additions to the executive team underscore Clinilabs’ commitment to strengthening its leadership and commercial capabilities in support of continued growth.
David Hagerman brings over 25 years of financial leadership experience across the life sciences and IT sectors. As CFO, he will oversee all financial operations and play a key role in driving long-term strategic and financial performance. Prior to joining Clinilabs, Mr. Hagerman served as CFO at X-Chem and held senior leadership roles at Charles River Laboratories and Parexel. He began his career at IBM, where he spent 16 years in progressively more senior financial roles.
“It is a pleasure to add Dave to our senior management team. He brings an incredible skill set to Clinilabs that aligns with our vision for growth and expansion,” said Dr. Gary Zammit, President and Chief Executive Officer of Clinilabs.
Jeanine M. Falinski, MBA, steps into the role of Senior Vice President of Commercial Development with more than 20 years of pharmaceutical industry experience. She originally joined Clinilabs in 2004 as Manager of Subject Recruitment and has since held several leadership roles, including Senior Director of Marketing and Communications and Senior Director of Business Development. After gaining additional commercial development experience at Evolution Research Group and Artcraft Health, she returned to Clinilabs in 2019 to lead the Company’s marketing efforts and is now expanding her role to manage the commercial team.
“Since assuming her latest leadership role, Jeanine has delivered tremendous value to our commercial organization,” said Dr. Zammit. “Her strategic leadership has elevated our level of customer engagement and will continue to support our mission of delivering high-quality, timely, and cost-effective drug, device and technology development services to clients worldwide.”
